The world health organization (WHO) has welcomed the encouraging results of a British study on the treatment of Covid-19-patients with the active ingredient dexamethasone. It was a "life-saving scientific breakthrough," said WHO chief Tedros Adhanom Ghebreyesus in the night to Wednesday in Geneva. Reuters/WHO/Christopher Black/WHO/Christopher Black/AP/dpa, The Director-General of the world health organization, Tedros Adhanom Ghebreyesus, warns in the fight against the Coronavirus pandemic of carelessness.
dexamethasone is the first form of treatment, the death rate of respiration machines connected Covid-19-detected patients dimensions sink. Tedros spoke of the "great news" and congratulated the UK government.
researchers led by a team at the University of Oxford had administered for the government-financed study, the widely available drug for ten days, more than 2000 with the Coronavirus-infected patients. Accordingly, dexamethasone reduced the mortality rate of the ventilator-dependent patient is 35 percent. For patients with only oxygen were administered, reduced the mortality rate by a fifth.
In patients with a milder disease course of dexamethasone, however, showed no effect. As a control, the researchers studied 4000 patients that were not treated with dexamethasone. Detailed Reviews of the clinical trial have not been published yet.
The scientists celebrated the discovery as a "major breakthrough" in the fight against the novel Coronavirus, the disease brought. They emphasised that dexamethasone is readily available and inexpensive. The British government put the funds immediately to the list of standard procedures of the National health service NHS counter-Covid-19.
All other messages to the Corona-crisis in Germany, Europe and the world, you will find in the News Ticker of FOCUS Online.
lightning recipe for quiche: The fast Alternative to the Alsatian classic PCP lightning recipe for quiche: The fast Alternative to the Alsatian classic
All of the important messages to the Coronavirus in the FOCUS Online Newsletter. Subscribe now.